| answer text |
<p>The level of funding for products undergoing review by NHS England will be determined
during the 2019/20 planning process.</p><p> </p><p>In 2016/17 and 2017/18, £25 million
was set aside for discretionary investment in new specialised services. This was determined
by NHS England, who considered it an appropriate level of investment in the context
of NHS England’s Specialised Commissioning functioning having to achieve overall efficiency
savings of approximately 2.5% and 2.7% in 2016/17 and 2017/18 respectively in order
to meet the financial pressures resulting from demographic growth and the legal requirement
to fund all positive National Institute for Health and Care Excellence technology
appraisals.</p><p> </p><p>The split in the overall funding available between the November
and May prioritisation rounds is not fixed but determined each year based on the number
and estimated cost of treatments being considered by the independently chaired Clinical
Priorities Advisory Group (CPAG) in each round. Revealing the split risks revealing
commercial in confidence information around pricing. Anything that is not prioritised
in the November round has the opportunity to be considered at the May round therefore
ensuring consideration against the full funding envelope for the financial year.</p><p>
</p><p>Where manufacturers have requested the cover sheets of the policy propositions,
they have received the CPAG summary report as presented at the May 2018 meeting from
NHS England.</p><p> </p><p>The full scoring methodology that is used at all prioritisation
meetings is published on the NHS England website. This can be found at the following
link:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/prioritisation-method-cons-response.pdf"
target="_blank">https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/06/prioritisation-method-cons-response.pdf</a></p><p>
</p><p>The outcome of the May 2018 prioritisation process through use of this methodology
has been published as a ranked list of five prioritisation Levels. This can be found
at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/2017/12/nhs-england-announces-new-specialised-treatments-for-patients/"
target="_blank">https://www.england.nhs.uk/2017/12/nhs-england-announces-new-specialised-treatments-for-patients/</a></p><p>
</p><p>The impact assessments for all the treatments include a narrative about the
estimated forecast financial implications for each item, based on the list price.
These are published as part of the public consultation pack. The detailed costings
are not shared as in many cases these are based on discount prices provided on a commercial
in confidence basis.</p><p> </p><p>The methodology for relative prioritisation has
been subject to legal advice as part of its development and implementation, and NHS
England believes it complies with equalities legislation, the NHS Constitution and
human rights legislation.</p><p> </p><p>NHS England routinely publishes the stakeholder
engagement response report as part of consultation through policy development, but
does not routinely publish any responses that arise as a result of public consultation.</p><p>
</p><p>NHS England has no plans to introduce a revised decision-making process for
ultra-orphan medicines as introduced in Scotland following the Montgomery Review.
NHS England will continue to use the methodology for prioritisation that has previously
been publicly consulted on.</p>
|
|
